Immunovaccine, Inc. - Product Pipeline Review - 2014

Published: Jul, 2014 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Immunovaccine, Inc. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Immunovaccine, Inc. - Product Pipeline Review - 2014', provides an overview of the Immunovaccine, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Immunovaccine, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Immunovaccine, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Immunovaccine, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Immunovaccine, Inc.'s pipeline products

Reasons to buy

- Evaluate Immunovaccine, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Immunovaccine, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Immunovaccine, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Immunovaccine, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Immunovaccine, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Immunovaccine, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Immunovaccine, Inc. Snapshot 5
Immunovaccine, Inc. Overview 5
Key Information 5
Key Facts 5
Immunovaccine, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Immunovaccine, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Immunovaccine, Inc. - Pipeline Products Glance 13
Immunovaccine, Inc. - Clinical Stage Pipeline Products 13
Phase I Products/Combination Treatment Modalities 13
Immunovaccine, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Immunovaccine, Inc. - Drug Profiles 16
DPX-Survivac 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
DPX-0907 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Anthrax Vaccine 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Subunit Vaccine for H5N1 Pandemic Influenza 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Subunit Vaccine for Hepatitis B 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Subunit Vaccine for Malaria 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Subunit Vaccine for Respiratory Syncytial Virus 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Vaccine for Cocaine Addiction 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Dengue Fever Vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Subunit Vaccine for Herpes Simplex Virus 2 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Subunit Vaccine for Multifiloviruses 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Subunit Vaccine for Tuberculosis 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Immunovaccine, Inc. - Pipeline Analysis 31
Immunovaccine, Inc. - Pipeline Products by Target 31
Immunovaccine, Inc. - Pipeline Products by Route of Administration 32
Immunovaccine, Inc. - Pipeline Products by Molecule Type 33
Immunovaccine, Inc. - Recent Pipeline Updates 34
Immunovaccine, Inc. - Dormant Projects 40
Immunovaccine, Inc. - Discontinued Pipeline Products 41
Discontinued Pipeline Product Profiles 41
Subunit Vaccine for Pseudomonas 41
Immunovaccine, Inc. - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 44
Disclaimer 44

List of Tables
Immunovaccine, Inc., Key Information 5
Immunovaccine, Inc., Key Facts 5
Immunovaccine, Inc. - Pipeline by Indication, 2014 8
Immunovaccine, Inc. - Pipeline by Stage of Development, 2014 9
Immunovaccine, Inc. - Monotherapy Products in Pipeline, 2014 10
Immunovaccine, Inc. - Partnered Products in Pipeline, 2014 11
Immunovaccine, Inc. - Partnered Products/ Combination Treatment Modalities, 2014 12
Immunovaccine, Inc. - Phase I, 2014 13
Immunovaccine, Inc. - Preclinical, 2014 14
Immunovaccine, Inc. - Discovery, 2014 15
Immunovaccine, Inc. - Pipeline by Target, 2014 31
Immunovaccine, Inc. - Pipeline by Route of Administration, 2014 32
Immunovaccine, Inc. - Pipeline by Molecule Type, 2014 33
Immunovaccine, Inc. - Recent Pipeline Updates, 2014 34
Immunovaccine, Inc. - Dormant Developmental Projects,2014 40
Immunovaccine, Inc. - Discontinued Pipeline Products, 2014 41